Alumis and ACELYRIN Revise Merger Agreement, Boosting ACELYRIN Stake
Shots:
- Alumis and ACELYRIN have amended their 2025 merger agreement, which originally granted ACELYRIN stockholders 0.4274 Alumis shares/share, giving them a 45% stake in the combined company
- As per the amendment, ACELYRIN stockholders will receive 0.4814 Alumis shares/share, allowing them to own 48% of the combined entity on a fully diluted basis; closing expected in Q2'25
- As of Dec 31, 2024, Alumis & ACELYRIN had a pro forma total of ~$737M to fund data readouts across clinical trials incl. lonigutamab & operations into 2027
Ref: Alumis | Image: Alumis & ACELYRIN
Related News:- Alumis and Kaken Pharmaceutical Enter Collaboration & Licencing Deal for ESK-001’s Development & Commercialization in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
